Clinical trials: Vasopressin Deficiency
Diabetes Insipidus, Diabetes Insipidus, Neurohypophyseal
Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus
OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone.
- Trial name
- NCT00004363
- Testing
- chlorpropamide, desmopressin
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Central Diabetes Insipidus
Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients.
- Trial name
- OxyMAX (NCT06789705)
- Testing
- MDMA
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hypopituitarism, Central Diabetes Insipidus
Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)
Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function.
- Conditions
- Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism, Psychological Disorder
- Trial name
- NCT04902235
- Testing
- Experimental: CRH administration
- Where
- Spain
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Diabetes Insipidus
Copeptin After a Subcutaneous Stimulation With Glucagon in Adults
This study is to evaluate copeptin values after the subcutaneous injection of glucagon in adults (healthy volunteers and patients with diabetes insipidus or primary polydipsia).
- Trial name
- Glucacop (NCT04550520)
- Testing
- Glucagon
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Arginine Vasopressin Deficiency, Primary Polydipsia
Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome
The aim of this study is to investigate whether oral urea stimulates copeptin release and, if so, whether it may provide a novel diagnostic test in the differentiation between AVP-D (Arginine vasopressin deficiency) and PP…
- Trial name
- URANOS (NCT05890690)
- Testing
- Urea
- Where
- Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Sellar and Suprasellar Masses, Pituitary Tumor
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2.
- Trial name
- NCT04369703
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Mayo Clinic